BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson’s Disease

D. Luke Fischer,Peggy Auinger,John L. Goudreau,Allyson Cole-Strauss,Karl Kieburtz,Jordan J. Elm,Mallory L. Hacker,P. David Charles,Jack W. Lipton,Barbara A. Pickut,Caryl E. Sortwell
DOI: https://doi.org/10.1007/s13311-020-00965-9
IF: 6.088
2020-10-01
Neurotherapeutics
Abstract:Disease outcomes are heterogeneous in Parkinson's disease and may be predicted by gene variants. This study investigated if the <i>BDNF</i> rs6265 single nucleotide polymorphism (SNP) is associated with differential outcomes with specific pharmacotherapy treatment strategies in the "NIH Exploratory Trials in PD Long-term Study 1" (NET-PD LS-1, <i>n</i> = 540). DNA samples were genotyped for the rs6265 SNP and others (rs11030094, rs10501087, rs1491850, rs908867, and rs1157659). The primary measures were the Unified Parkinson's Disease Rating Scale (UPDRS) and its motor component (UPDRS-III). Groups were divided by genotype and treatment regimen (levodopa monotherapy <i>vs</i> levodopa with other medications <i>vs</i> no levodopa). T allele carriers were associated with worse UPDRS outcomes compared to C/C subjects when treated with levodopa monotherapy (+ 6 points, <i>p</i> = 0.02) and to T allele carriers treated with no levodopa treatment strategies (UPDRS: + 8 points, <i>p</i> = 0.01; UPDRS-III: + 6 points, <i>p</i> = 0.01). Similar effects of worse outcomes associated with levodopa monotherapy were observed in the <i>BDNF</i> rs11030094, rs10501087, and rs1491850 SNPs. This study suggests the levodopa monotherapy strategy is associated with worse disease outcomes in <i>BDNF</i> rs6265 T carriers. Pending prospective validation, <i>BDNF</i> variants may be precision medicine factors to consider for symptomatic treatment decisions for early-stage PD patients.
pharmacology & pharmacy,neurosciences,clinical neurology
What problem does this paper attempt to address?